CROMSOURCE’s overall therapeutic expertise includes the management of pharmaceutical trials in a variety of rare disease indications. With proven expertise in finding and recruiting the right patients to these challenging studies, CROMSOURCE supports such projects with our trusted methodology, which involves detailed project planning, protocol assessment, logistical analysis and the execution of all aspects of your clinical trial.
Most often, the major challenges inherent in completion of studies in rare diseases result from two factors; a limited patient population with a wide geographical spread. In order to address these challenges, the first step is to conduct a thorough feasibility analysis. With our Feasibility Plus approach, CROMSOURCE is able to not only identify and quantify the available patient population but also to expertly examine other key facets of the project, such as the clinical acceptability of the protocol, the availability and experience of the investigators, the existence of competing research, and the applicable regulatory landscape of each potential country. These data are iteratively analysed to create various operational strategies, providing our clients with reliable overall timelines and budgets for each scenario. When feasibility is so crucial to success, it makes sense to work with CROMSOURCE, the industry leaders in feasibility and trial planning.
CROMSOURCE’s Rare Disease & Orphan Drug experience includes a history of more than 35 studies in a broad range of indications, including but not limited to:
- Acute Leukemia
- Alpha-1 antitrypsin deficiency
- Amyotrophic Lateral Sclerosis
- Cystic fibrosis
- Duchenne Muscular Dystrophy
- Lupus
- Multiple System Atrophy
- Myasthenia Gravis
- Retinitis pigmentosa
- Rhesus Disease
